Goel Amit, Verma Alka, Tiwari Prachi, Katiyar Harshita, Aggarwal Amita, Khetan Dheeraj, Kishore Ravi V Krishna, Kumar Pankaj, Singh Thakur Prashant, Sheikh Sabreena, Vaishnav Manas, Pathak Piyush
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India.
Department of Emergency Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India.
Vaccines (Basel). 2022 Oct 30;10(11):1837. doi: 10.3390/vaccines10111837.
Introduction: Data are limited on antibody response to the ChAdOx1 nCoV-19 vaccine (AZD1222; Covishield®) in cirrhosis. We studied the antibody response following two doses of the ChAdOx1 vaccine, given 4−12 weeks apart, in cirrhosis. Methods: Prospectively enrolled, 131 participants (71% males; age 50 (43−58); alcohol-related etiology 14, hepatitis B 33, hepatitis C 46, cryptogenic 21, autoimmune 9, others 8; Child−Turcott−Pugh class A/B/C 52/63/16). According to dose intervals, the participants were grouped as ≤6 weeks (group I), 7−12 weeks (group II), and 13−36 weeks (group III). Blood specimens collected at ≥4 weeks after the second dose were tested for anti-spike antibody titre (ASAb; positive ≥ 0.80 U/mL) and neutralizing antibody (NAb; positive ≥20% neutralization) using Elecsys Anti-SARS-CoV-2 S (Roche) and SARS-CoV-2 NAb ELISA Kit (Invitrogen), respectively. Data are expressed as number (proportion) and median (interquartile range) and compared using non-parametric tests. Results: Overall, 99.2% and 84% patients developed ASAb (titre 5440 (1719−9980 U/mL)) and NAb (92 (49.1−97.6%)), respectively. When comparing between the study groups, the ASAb titres were significantly higher in group II than in group I (2613 (310−7518) versus 6365 (2968−9463), p = 0.027) but were comparable between group II and III (6365 (2968−9463) versus 5267 (1739−11,653), p = 0.999). Similarly, NAb was higher in group II than in group I (95.5 (57.6−98.0) versus 45.9 (15.4−92.0); p < 0.001), but not between the groups II and III (95.5 (57.6−98.0) versus 92.4 (73.8−97.5); p = 0.386). Conclusion: Covishield® induces high titres of ASAb and NAb in cirrhosis. A higher titre is achieved if two doses are given at an interval of more than six weeks.
关于肝硬化患者对ChAdOx1 nCoV-19疫苗（AZD1222；Covishield®）的抗体反应的数据有限。我们研究了在肝硬化患者中，间隔4至12周接种两剂ChAdOx1疫苗后的抗体反应。方法：前瞻性招募了131名参与者（71%为男性；年龄50岁（43 - 58岁）；酒精相关病因14例，乙型肝炎33例，丙型肝炎46例，隐源性21例，自身免疫性9例，其他8例；Child-Turcott-Pugh A/B/C级分别为52/63/16例）。根据剂量间隔，参与者被分为≤6周组（I组）、7至12周组（II组）和13至36周组（III组）。在第二剂疫苗接种后≥4周采集的血液标本，分别使用Elecsys Anti-SARS-CoV-2 S（罗氏公司）和SARS-CoV-2 NAb ELISA试剂盒（英杰公司）检测抗刺突抗体滴度（ASAb；阳性标准≥0.80 U/mL）和中和抗体（NAb；阳性标准≥20%中和率）。数据以数量（比例）和中位数（四分位间距）表示，并使用非参数检验进行比较。结果：总体而言，分别有99.2%和84%的患者产生了ASAb（滴度为5440（1719 - 9980 U/mL））和NAb（92（49.1 - 97.6%））。在研究组之间进行比较时，II组的ASAb滴度显著高于I组（2613（310 - 7518）对6365（2968 - 9463），p = 0.027），但II组和III组之间相当（6365（2968 - 9463）对5267（1739 - 11,653），p = 0.999）。同样，II组的NAb高于I组（95.5（57.6 - 98.0）对45.9（15.4 - 92.0）；p < 0.001），但II组和III组之间无差异（95.5（57.6 - 98.0）对92.4（73.8 - 97.5）；p = 0.386）。结论：Covishield®在肝硬化患者中诱导产生高滴度的ASAb和NAb。如果两剂疫苗间隔超过六周接种，则可获得更高滴度。
